HomeCompareSLRX vs MO

SLRX vs MO: Dividend Comparison 2026

SLRX yields 238.10% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRX wins by $339.52M in total portfolio value
10 years
SLRX
SLRX
● Live price
238.10%
Share price
$0.84
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$339.60M
Annual income
$185,958,933.65
Full SLRX calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — SLRX vs MO

📍 SLRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRXMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRX + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRX pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRX
Annual income on $10K today (after 15% tax)
$20,238.10/yr
After 10yr DRIP, annual income (after tax)
$158,065,093.60/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, SLRX beats the other by $158,039,458.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRX + MO for your $10,000?

SLRX: 50%MO: 50%
100% MO50/50100% SLRX
Portfolio after 10yr
$169.84M
Annual income
$92,994,546.40/yr
Blended yield
54.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

SLRX
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-14.5
Piotroski
3/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRX buys
0
MO buys
0
No recent congressional trades found for SLRX or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRXMO
Forward yield238.10%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$339.60M$80.1K
Annual income after 10y$185,958,933.65$30,159.17
Total dividends collected$322.91M$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: SLRX vs MO ($10,000, DRIP)

YearSLRX PortfolioSLRX Income/yrMO PortfolioMO Income/yrGap
1← crossover$34,510$23,809.52$10,570$780.30+$23.9KSLRX
2$113,715$76,790.22$11,381$1,032.90+$102.3KSLRX
3$358,160$236,484.38$12,535$1,392.73+$345.6KSLRX
4$1,079,339$696,107.48$14,193$1,920.91+$1.07MSLRX
5$3,115,421$1,960,529.07$16,618$2,723.68+$3.10MSLRX
6$8,622,197$5,288,696.04$20,263$3,993.80+$8.60MSLRX
7$22,905,117$13,679,366.22$25,936$6,098.36+$22.88MSLRX
8$58,470,750$33,962,275.23$35,166$9,775.01+$58.44MSLRX
9$143,588,724$81,025,021.41$51,026$16,597.78+$143.54MSLRX
10$339,598,869$185,958,933.65$80,113$30,159.17+$339.52MSLRX

SLRX vs MO: Complete Analysis 2026

SLRXStock

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Full SLRX Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this SLRX vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRX vs SCHDSLRX vs JEPISLRX vs OSLRX vs KOSLRX vs MAINSLRX vs PMSLRX vs BTISLRX vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.